Inflection Point Ventures (IPV), a domestic angel investment platform, has announced the launch of IPV International, a $110 million Category I Angel Fund registered under the International Financial Services Centres Authority (IFSCA) in GIFT City, Gujarat.
The fund completed its first close in April 2025 and has made its first overseas investment in Cellivate Technologies, a Singapore-based deeptech company. Cellivate is developing a patented alternative to fetal bovine serum for use in biotech and pharmaceutical applications.
Designed to invest in early to pre-Series A rounds, IPV International will allocate capital across global startups, with investment sizes ranging from $100,000 to $1 million. The fund has received both the Fund Registration Certificate and Fund Management Entity (FME) license from IFSCA, allowing it to operate within GIFT City’s regulatory framework.
According to IPV, the fund aims to facilitate cross-border investments and widen participation from investors based in India and abroad. The IFSCA setup permits investment without the need for a PAN card or Indian tax filings, as long as the investor’s income from India is restricted to GIFT City-based activity.
IPV co-founders said the new fund would follow the firm’s existing investment model, focusing on sector-agnostic opportunities and applying structured due diligence processes.
Inflection Point Ventures currently has a network of over 24,000 investors and a portfolio of more than 220 startups. The firm has also launched a separate $50 million venture capital fund, Physis Capital, focused on growth-stage investments.
